Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone732-549-0128
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees19
Next Earnings DateN/A
OptionableNot Optionable
Echo Therapeutics (OTCMKTS:ECTE) Frequently Asked Questions
What is Echo Therapeutics' stock symbol?
Echo Therapeutics trades on the OTCMKTS under the ticker symbol "ECTE."
How were Echo Therapeutics' earnings last quarter?
Echo Therapeutics Inc (OTCMKTS:ECTE) released its quarterly earnings data on Friday, August, 12th. The medical device company reported ($0.82) earnings per share for the quarter. During the same quarter last year, the firm posted ($0.97) EPS. View Echo Therapeutics' Earnings History.
Has Echo Therapeutics been receiving favorable news coverage?
Media headlines about ECTE stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Echo Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Echo Therapeutics' key competitors?
What other stocks do shareholders of Echo Therapeutics own?
Who are Echo Therapeutics' key executives?
Echo Therapeutics' management team includes the folowing people:
- Mr. Alan W. Schoenbart CPA, Chief Exec. Officer, Chief Financial Officer and Director (Age 60)
How do I buy shares of Echo Therapeutics?
Shares of ECTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Echo Therapeutics' stock price today?
One share of ECTE stock can currently be purchased for approximately $0.0060.
How big of a company is Echo Therapeutics?
Echo Therapeutics has a market capitalization of $79,782.00. Echo Therapeutics employs 19 workers across the globe.
What is Echo Therapeutics' official website?
How can I contact Echo Therapeutics?
Echo Therapeutics' mailing address is 99 WOOD AVENUE SOUTH SUITE 302, ISELIN NJ, 08830. The medical device company can be reached via phone at 732-549-0128 or via email at [email protected]
MarketBeat Community Rating for Echo Therapeutics (OTCMKTS ECTE)
MarketBeat's community ratings are surveys of what our community members think about Echo Therapeutics and other stocks. Vote "Outperform" if you believe ECTE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECTE will underperform the S&P 500 over the long term. You may vote once every thirty days.
